Lates News

According to the AI News of TodoEmprende, Huayuan Securities released a research report on April 2, giving a "buy" rating to Kelaiying (002821.SZ). The main reasons for this rating include: 1) Kelaiying is a globally leading CDMO one-stop comprehensive solution provider, dedicated to technological innovation and commercial application of global pharmaceutical processes; 2) the company achieves rapid growth in emerging businesses by leveraging industry resources and competitive advantages accumulated in the small molecule CDMO business sector; 3) high-order growth rate, emerging businesses contribute to order increments, and production capacity continues to be invested in. (Everyday Economic News)